Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review

• Published in: Autoimmunity reviews Vol. 20; no. 6; p. 102831
• Main Authors: Escobar-Soto, Carlos-Hugo, Mejia-Romero, Rossana, Aguilera, Natalia, Alzate-Granados, Juan Pablo, Mendoza-Pinto, Claudia, Munguía-Realpozo, Pamela, Méndez-Martínez, Socorro, García-Carrasco, Mario, Rojas-Villarraga, Adriana
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2021
• Subjects: Cell transplantation; Mesenchymal stem cell transplantation; Mesenchymal stromal; Scleroderma; Mesenchymal stromal; Scleroderma; Mesenchymal stem cell transplantation; Cell transplantation
• ISSN: 1568-9972; 1568-9972; 1873-0183
• DOI: 10.1016/j.autrev.2021.102831

Sistemic Sclerosis (SSc) is a heterogeneous autoimmune disease with a high rate of progression and therapeutic failure, and treatment is a challenge, new therapeutic proposals being needed, being mesenchymal stem cells (MSCs) considered as alternative therapy for SSc for its immunomodulatory capacity. We evaluated the efficacy and safety of human MSC (hMSC) in patients with SSc through a systematic literature review (SLR). SLR (PRISMA guideline) on MEDLINE/OVID, LILACS, EMBASE, and Cochrane/OVID bases (until July 2020, without limits). All types of clinical studies were considered: patients ≥18 years old with SSc and treatment with hMSC. Exclusion criteria: animal models, autologous/allogenic hematopoietic stem cell transplants, narrative reviews, letters to the editor. MeSH and “Key word” terms were used. The level of evidence and the quality rating were rated [Joanna Briggs Institute (JBI) lists]. Registration in PROSPERO repository (ID CRD42020185245) The Synthesis Without Meta-analysis (SWiM) guideline was followed. We initially identified 508 articles, of which 11 were finally included (8 case series and 3 case reports). The 11 articles included 101 patients (85 female, age range 18–75 years). The level of evidence was mostly 4 (JBI); the quality of evidence was met (≥50% of JBI items). SWiM showed that vascular skin involvement (digital ulcers, necrosis, and gangrene) and associated pain were the predominant outcomes, while improvements were found in almost all cases. One patient died in the first month, and the frequency of complications was low. Expanded hMSCs were used in 24 patients and other cell sources in the remaining patients. There is too little reported data to reach definite conclusions about the use of hMSC in SSc. Further studies with better epidemiological designs are needed to evaluate the benefit of hMSCs in SSc patients. •The hMSC in SSc have the capacity of modify the functioning of immune system cells and proinflammatory cytokines production.•The extraction and routes of application of mesenchymal cells for the treatment of SSc is heterogeneous.•It has been reported that the use of hMSC in SSc improve the size of ulcers, pain and vascular flow.